INZY (Inozyme Pharma) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Inozyme Pharma is: No Data: Cannot be evaluated.

Competitive Comparison of Inozyme Pharma's Risk Assessment

For the Biotechnology subindustry, Inozyme Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inozyme Pharma's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Inozyme Pharma's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Inozyme Pharma (NAS:INZY) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Inozyme Pharma Risk Assessment Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Inozyme Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Summer Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.inozyme.com

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

Executives

Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Robert Lorne Hopfner	director, 10 percent owner	C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton	officer: COO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian	officer: SVP, CFO	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke	officer: See Remarks	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte	director, 10 percent owner, officer: See Remarks	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc.	director	321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert	officer: SVP, CMO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell	10 percent owner